Sofosbuvir for previously untreated chronic hepatitis C infection

Clicks: 452
ID: 273565
2013
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #47 of 183 articles by views in The New England journal of medicine

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 183 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In a single-group study of sofosbuvir combined with peginterferon-ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks. In a noninferiority trial, patients with genotype 2 or 3 infection who received either sofosbuvir or p …
Reference Key
e2013thesofosbuvir Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Lawitz E;Mangia A;Wyles D;Rodriguez-Torres M;Hassanein T;Gordon SC;Schultz M;Davis MN;Kayali Z;Reddy KR;Jacobson IM;Kowdley KV;Nyberg L;Subramanian GM;Hyland RH;Arterburn S;Jiang D;McNally J;Brainard D;Symonds WT;McHutchison JG;Sheikh AM;Younossi Z;Gane EJ;;
Journal The New England journal of medicine
Year 2013
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/23607594
Keywords
hepatitis c National Center for Biotechnology Information NCBI NLM MEDLINE RNA humans pubmed abstract nih national institutes of health national library of medicine logistic models research support non-u.s. gov't adult female male aged middle aged young adult Clinical Trial Phase III Randomized Controlled Trial Multicenter Study Genotype viral / blood drug therapy combination antiviral agents / therapeutic use* ribavirin / therapeutic use* recombinant proteins / adverse effects recombinant proteins / therapeutic use chronic / virology antiviral agents / adverse effects hepacivirus / genetics* chronic / drug therapy* interferon-alpha / adverse effects interferon-alpha / therapeutic use* polyethylene glycols / adverse effects polyethylene glycols / therapeutic use* ribavirin / adverse effects eric lawitz alessandra mangia liver cirrhosis / virology sofosbuvir uridine monophosphate / analogs & derivatives* uridine monophosphate / therapeutic use pmid:23607594 doi:10.1056/nejmoa1214853 edward j gane uridine monophosphate / adverse effects

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.